MedTrace Logo

Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors

NCT07401316 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-05-04

No results posted yet for this study

Summary

This study will evaluate the utility of ctDNA detection in patients with high-risk stage I, stage II, and stage III germ cell tumor disease to develop a tool for post-treatment cancer cell detection.

Conditions

  • Germ Cell Cancer Metastatic

Interventions

DIAGNOSTIC_TEST

Whole blood for ctDNA

Whole blood for ctDNA

Sponsors & Collaborators

  • Natera, Inc.

    collaborator INDUSTRY

  • Indiana University

    lead OTHER

Principal Investigators

  • Nabil Adra, MD · Indiana University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2032-12-31
Completion
2032-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07401316 on ClinicalTrials.gov